Cadrenal Therapeutics Stock Target Price and Analyst Consensus
| CVKD Stock | 5.54 0.12 2.21% |
The current analyst and expert consensus on Cadrenal Therapeutics is Strong Buy, with only one strong buy opinion. The current projected Cadrenal Therapeutics target price consensus is 37.50 with 2 analyst opinions. Check out Macroaxis Advice on Cadrenal Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Cadrenal Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Cadrenal Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Cadrenal Therapeutics. We encourage you to use your own analysis of Cadrenal Therapeutics to validate this analysis. Cadrenal Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Cadrenal Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 7.4409.
Lowest Forecast 34.13 | Highest Forecast 41.63 | Target Price 37.5 |
It's important to approach Cadrenal Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Cadrenal Therapeutics Target Price Consensus
Cadrenal target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cadrenal Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Cadrenal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cadrenal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cadrenal Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCadrenal Therapeutics Target Price Projection
Cadrenal Therapeutics' current and average target prices are 5.54 and 37.50, respectively. The current price of Cadrenal Therapeutics is the price at which Cadrenal Therapeutics Common is currently trading. On the other hand, Cadrenal Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cadrenal Therapeutics Market Quote on 17th of February 2026
Target Price
Analyst Consensus On Cadrenal Therapeutics Target Price
Cadrenal Therapeutics Analyst Ratings
Cadrenal Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Cadrenal Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Cadrenal Therapeutics' financials, market performance, and future outlook by experienced professionals. Cadrenal Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Cadrenal Therapeutics price targets
Cadrenal Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Cadrenal Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Cadrenal Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Cadrenal Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Cadrenal Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Cadrenal Therapeutics is a key component of Cadrenal Therapeutics valuation and have some predictive power on the future returns of a Cadrenal Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested over 90 shares | |
 | SRI Sustainable Growth Invested over 90 shares | |
 | ESG Investing Sold few shares | |
 | Social Domain Invested over 90 shares | |
Check out Macroaxis Advice on Cadrenal Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Please note, the presentation of Cadrenal Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cadrenal Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cadrenal Therapeutics' management manipulating its earnings.